(PDF) P2.13-42 Osimertinib Treatment for Patients With EGFR

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1437

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

A. Van Der Wekken

Publisher

Elsevier BV

Related search

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer in Korea

Cancer Research and Treatment

Cancer Research

English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health

Occupational Health

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancer Research

English

P3.15-03 Capturing the Patient Experience for the Treatment of EGFR Exon 20 Mutations in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-29 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Cancer Research

English

P2.13-13 Real-World Study of Osimertinib in EGFR T790m-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Oncology Reports

Cancer Research

English